Metalloenzyme inhibitor compounds
The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
1. A compound of formula (II):
wherein R 2 is optionally substituted aryl, optionally substituted naphthyl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl-alkyl;
R 3 is H, OH, alkoxy, amino, alkylamino, or dialkylamino;
R 4 is chloro;
R 5 is halogen, alkoxy, fluoroalkoxy containing 1-5 fluorines, cyano, carboxamido, optionally substituted aryl, or optionally substituted heteroaryl; and
R 6 is H, halogen, alkoxy, fluoroalkoxy containing 1-5 fluorines, cyano, carboxamido, optionally substituted aryl, or optionally substituted heteroaryl.
2. A compound that is:
1-(2-Chloro-thiazol-5-yl)-1-(6,7-dimethoxynaphthalen-2-yl)-2-methylpropan-1-ol (1); or
1-(6,7-dimethoxynaphthalen-2-yl)-2-methyl-1-(thiazol-5-yl)propan-1-ol (2).
3. A method of treating a subject suffering from a metalloenzyme-related disorder or disease, wherein the subject has been identified as in need of treatment for a metalloenzyme-related disorder or disease, comprising administering to said subject in need thereof, an effective amount of a compound of claim 1 , such that said subject is treated for said disorder;
wherein the disease or disorder is prostate cancer, breast cancer, testicular cancer, uterine cancer, or ovarian cancer.
4. The method of claim 3 , wherein the disease or disorder is prostate cancer.
5. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
6. The composition of claim 5 further comprising an additional therapeutic agent.
7. The composition of claim 6 further comprising an additional therapeutic agent that is an anti-cancer agent, antifungal agent, cardiovascular agent, antiinflammatory agent, chemotherapeutic agent, an anti-angiogenesis agent, cytotoxic agent, an anti-proliferation agent, metabolic disease agent, opthalmologic disease agent, central nervous system (CNS) disease agent, urologic disease agent, or gastrointestinal disease agent.
8. The compound of claim 1 , wherein R 3 is OH.
9. The compound of claim 1 , wherein R 2 is optionally substituted alkyl and R 3 is OH.
10. The compound of claim 1 , wherein R 2 is alkyl and R 3 is OH.